Shoe Carnival (NASDAQ:SCVL) – Equities researchers at Wedbush increased their Q2 2019 earnings per share (EPS) estimates for Shoe Carnival in a research note issued to investors on Friday, May 25th. Wedbush analyst C. Svezia now forecasts that the company will earn $0.55 per share for the quarter, up from their previous forecast of $0.45. Wedbush also issued estimates for Shoe Carnival’s Q3 2019 earnings at $0.64 EPS and FY2020 earnings at $2.24 EPS.
Get Shoe Carnival alerts:SCVL has been the subject of several other reports. ValuEngine lowered shares of Shoe Carnival from a “hold” rating to a “sell” rating in a report on Wednesday, May 2nd. Pivotal Research set a $30.00 price target on shares of Shoe Carnival and gave the company a “buy” rating in a report on Wednesday, March 28th. BidaskClub raised shares of Shoe Carnival from a “sell” rating to a “hold” rating in a report on Friday, February 9th. Zacks Investment Research lowered shares of Shoe Carnival from a “hold” rating to a “sell” rating in a report on Friday, March 30th. Finally, TheStreet lowered shares of Shoe Carnival from a “b” rating to a “c+” rating in a report on Wednesday, March 28th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $27.33.
Top 5 Medical Stocks To Buy Right Now: Newmont Mining Corporation(NEM)
Newmont Mining Corporation, together with its subsidiaries, operates in the mining industry. It primarily acquires, develops, explores for, and produces gold, silver, and copper. The company's operations and/or assets are located in the United States, Australia, Peru, Indonesia, Ghana, and Suriname. As of December 31, 2015, it had proven and probable gold reserves of 73.7 million ounces and an aggregate land position of approximately 20,000 square miles. The company was founded in 1916 and is headquartered in Greenwood Village, Colorado.
In fact, there couldn't be a better time to buy gold stocks, given the ongoing industry consolidation. Two massive recent deals -- Barrick Gold's (NYSE:GOLD) merger with Randgold Resources and Newmont Mining's (NYSE:NEM) impending acquisition of Goldcorp (NYSE:GG) -- are creating the world's two largest publicly traded gold mining companies. More recently, Barrick Gold even made a takeover bid for Newmont Mining, but the two gold mining giants have only agreed to combine their operations in Nevada in a joint venture as of this writing. These developments make investing in gold stocks now incredibly interesting. It's not every day that mining companies make the news here, and that's because investors are often better off ignoring them. But Barrick Gold (NYSE:GOLD) and Newmont Mining (NYSE:NEM) have been tying up in a big way, creating something to the tune of a $30 billion joint venture in the gold space. As of December 2017, Greenlight Re's major (10%+) long positions were General Motors (GM), Brighthouse Financial (BHF), gold (GLD), Bayer (OTCPK:BAYZF), and Mylan (MYL). It also holds a long position in Micron (MU), which was the best positive contributor to its portfolio in the first quarter of 2018. These long positions were balanced by shorts in Tesla (TSLA), Netflix (NFLX), and other "bubble basket" stocks. The portfolio is also short Assured Guaranty (AGO), a municipal bond insurer, a position which is hedged by a simultaneous long in Puerto Rican debt. Overall, the portfolio is 93% gross long and 65% gross short. Unlike most insurance portfolios, just 0.5% of investments are in debt instruments and, in fact, Greenlight Re's short portfolio was 11% allocated to sovereign debt. For the third quarter, the company reported cash and equivalents of $470.4 million, while net income came in at $50 million (includes a gain of $78.7 million from the Immunomedics' warrant). Without the one-time gain, its loss of $28.7 million would still be an improvement over net loss of $31.8 million for the same quarter last year. For the fourth quarter, the company is guiding for ADCETRIS sales in the range of $82 million to $84 million (total revenue of $128 million to $130 million). In addition to the growing opportunity for ADCETRIS (peak sales in excess of $1 billion) and the intriguing prospects of tucatinib, the company has a promising pipeline of ADC candidates and immuno-oncology assets. Partnered programs with the likes of AbbVie (NYSE:ABBV), Astellas (OTCPK:ALPMY), Genmab (OTCPK:GMXAY), Bayer (OTCPK:BAYZF), Genentech and many more also lend additional credibility to the story. We are a retailer and distributor of pharmaceutical and other healthcare products typically found in a retail pharmacy in the People's Republic of China ("PRC" or "China"). Prior to acquiring Zhejiang Jiuxin Medicine Co., Ltd. ("Jiuxin Medicine") in August 2011 (see "Our Corporate History and Structure - HJ Group" below), we were primarily a retail pharmacy operator. We currently have fifty eight (58) store locations under the store brand "Jiuzhou Grand Pharmacy" in Hangzhou. We currently operate in four business segments in China: (1) retail drugstores, (2) online pharmacy, (3) wholesale business selling products similar to those we carry in our pharmacies, and (4) farming and selling herbs used for traditional Chinese medicine ("TCM"). Advisors' Opinion: Press coverage about China Jo-Jo Drugstores (NASDAQ:CJJD) has trended positive on Saturday, Accern reports. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. China Jo-Jo Drugstores earned a media sentiment score of 0.28 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 48.5554072096128 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days. China accounted for 136k car sales (YoY -35.8%). The decline could be explained with a lag of new products which are now introduced step by step. The new Ford Focus (+94% Q12019/Q42018) and Ford Territory already gained momentum while the company continuously increases availability of the new models. "Ford China 2.0" is a strategy to drive sales and reshape the business. Ford will introduce 30 new models within three years of which 10 models will be electrified. With the new product lineup, Ford will compete with Daimler (OTCPK:DDAIF), Renault (OTC:RNSDF), BMW (OTCPK:BMWYY) and Tesla (NASDAQ:TSLA) and it is likely that it can increase market share in China again. Daimler (OTCPK:DDAIF) seems to offer a good risk to reward opportunity at the current price. In EUR terms, the stock trades about 40% lower compared to its peak in 2015 due to investors' concerns about the structural and cyclical issues as well as tariffs as of lately. Yet, with 6.2 P/E ratio and 6.7% dividend yield, it seems it is worth taking the risks. Workhorse Group (OTCMKTS: DDAIF) and Daimler (OTCMKTS:DDAIF) are both auto/tires/trucks companies, but which is the better investment? We will compare the two companies based on the strength of their risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability. By way of background, right now, Aston Martin's principal owners are an Italian private-equity fund, Investindustrial; a consortium led by Kuwaiti private-equity firm The Investment Dar (TID); and German automaker Daimler AG (NASDAQOTH:DDAIF), which owns a stake of about 4.9%. Several other private-equity firms hold smaller stakes. In April 2018, Nemaska (OTCQX:NMKEF) drew nearly $100 million in investment from Japan's SoftBank (OTCPK:SFTBY) group in exchange for a 9.9% interest in the company and access to lithium hydroxide produced by the company. In March 2018, CATL the world's soon-to-be largest lithium battery manufacturer purchased a controlling stake in the Quebec Lithium project in consideration for $66 million. In February 2018, Korean steel giant, POSCO (PKX) announced a supply agreement and investment into Australian lithium miner Pilbara Minerals (OTCPK:PILBF). In January 2018, Toyota Tsusho (OTCPK:TYHOF), the strategic trading arm of Toyota Motors, invested approximately A$300 million in Orocobre (OTCPK:OROCF) in consideration for 15% of the company. Now, in April 2018, Swedish battery start-up NorthVolt has announced that it has signed an agreement for the supply of up to 5,000 metric tons per year of lithium hydroxide produced at Nemaska Lithium's commercial plant in Shawinigan, Quebec. In connection with the supply of lithium chemicals, NorthVolt has agreed to deliver to Nemaska a 10 million euro promissory note that can be converted into voting shares of NorthVolt. Early-stage lithium producer Orocobre (OTCPK:OROCF) has been busy developing its Argentine flag-ship asset at Olaroz. The company has managed to scale up the asset to around 12,000 T / year LCE with a nameplate production capacity of 17,500 T / year. Although the company has not achieved full production capacity at its asset, it has moved ahead with joint venture partner Toyota Tsusho (OTCPK:TYHOF) to develop plans for Phase 2. In January 2018, Orocobre announced that Toyota Tsusho would invest nearly $300 million for a 15% stake in the company, along with plans to double production capacity at Olaroz to 42,000 T LCE / year. The joint venture is also building a lithium hydroxide facility in Japan which will supply the local battery supply chain.Top 5 Medical Stocks To Buy Right Now: Bayer Aktiengesellschaft (BAYZF)
Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, adhesives and sealants; and selected chemical intermediates. Advisors' Opinion: Top 5 Medical Stocks To Buy Right Now: China Jo-Jo Drugstores, Inc.(CJJD)
Top 5 Medical Stocks To Buy Right Now: Daimler AG (DDAIF)
Daimler AG (Daimler) is an automotive engineering company. The Company is engaged in the development, production and distribution of cars, trucks and vans in Germany, and the management of the Daimler Group. Daimler's segments include Mercedes-Benz Cars, Daimler Trucks, Mercedes-Benz Vans, Daimler Buses and Daimler Financial Services. The products supplied by the Mercedes-Benz Cars division include a spectrum of premium vehicles of the Mercedes Benz brand and its Mercedes AMG, and Mercedes Maybach sub brands. Daimler Trucks distribute its trucks under the brand names, Mercedes Benz, Freightliner, FUSO, Western Star, Thomas Built Buses and BharatBenz. The vans of the Mercedes Benz Vans segment are sold under the brand names, Mercedes Benz Freightliner brand. Daimler Buses sell completely built up buses under the brand names, Mercedes Benz and Setra. The Daimler Financial Services segment supports the sales of the Company's vehicle segments in over 40 countries. Advisors' Opinion: Top 5 Medical Stocks To Buy Right Now: Orocobre Limited (OROCF)
Orocobre Limited operates primarily in Argentina in the mining industry. The Company engages in the production ramp up of its Olaroz Lithium Facility and the operation of Borax Argentina S.A. (Borax Argentina). Its segments include Corporate, the Olaroz project, South American Salars and Borax Argentina. Its primary focus is on exploration for and development of lithium, potash and salar mineral deposits. The Company's assets also include boron mines and processing facilities of Borax Argentina and a portfolio of brine exploration projects. Its Olaroz Lithium Facility is located in the Puna region of Jujuy Province in northern Argentina, over 230 kilometers northwest of the capital city of Jujuy. Borax Argentina operates over three open pit mines in Tincalayu, Sijes and Porvenir. Borax Argentina produces products, including minerals, such as ulexite, colemanite and hydroboracite; refined products, such as borax decahydrate, borax pentahydrate and borax anhydrous, and boric acid. Advisors' Opinion:
No comments:
Post a Comment